- Home
- RNXT
RNXT
RenovoRx Inc.
as 05-09-2025 12:43pm EST
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Upcoming Earnings Alert:
Get ready for potential market movements as RenovoRx Inc. RNXT prepares to release earnings report on 15 May 2025.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | MOUNTAIN VIEW |
| Market Cap: | 37.6M | IPO Year: | 2021 |
| Target Price: | $7.00 | AVG Volume (30 days): | 112.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.75 - $1.69 | Next Earning Date: | 05-15-2025 |
| Revenue: | $43,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | 4755.81% | Revenue Growth (next year): | 187.93% |
Stock Insider Trading Activity of RenovoRx Inc. (RNXT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Agah Ramtin | RNXT | Chief Medical Officer | Apr 15 '25 | Buy | $0.90 | 15,000 | $13,500.00 | 1,113,460 | |
| Bagai Shaun | RNXT | Chief Executive Officer | Apr 15 '25 | Buy | $0.91 | 7,500 | $6,821.25 | 320,040 | |
| Agah Ramtin | RNXT | Chief Medical Officer | Apr 11 '25 | Buy | $0.80 | 20,000 | $16,000.00 | 1,113,460 | |
| Agah Ramtin | RNXT | Chief Medical Officer | Apr 9 '25 | Buy | $0.81 | 30,000 | $24,399.00 | 1,113,460 | |
| Bagai Shaun | RNXT | Chief Executive Officer | Apr 9 '25 | Buy | $0.83 | 10,000 | $8,300.00 | 320,040 | |
| Agah Ramtin | RNXT | Chief Medical Officer | Apr 8 '25 | Buy | $0.84 | 26,000 | $21,840.00 | 1,113,460 | |
| Kocak Ron | RNXT | VP Controller and PAO | Apr 8 '25 | Buy | $0.80 | 12,595 | $10,011.00 | 95 | |
| Marton Laurence | RNXT | Director | Apr 8 '25 | Buy | $0.85 | 12,050 | $10,218.40 | 45,684 | |
| Bagai Shaun | RNXT | Chief Executive Officer | Apr 7 '25 | Buy | $0.83 | 10,000 | $8,300.00 | 320,040 |
Latest RenovoRx Inc. News
RNXT Breaking Stock News: Dive into RNXT Ticker-Specific Updates for Smart Investing
Argus Research
7 hours ago
Daily – Vickers Top Insider Picks for 05/09/2025
Argus Research
a day ago
Daily – Vickers Top Insider Picks for 05/08/2025
Argus Research
2 days ago
Daily – Vickers Top Insider Picks for 05/07/2025
Business Wire
3 days ago
U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform
Argus Research
3 days ago
Daily – Vickers Top Insider Picks for 05/06/2025
Argus Research
4 days ago
Daily – Vickers Top Insider Picks for 05/05/2025
Argus Research
7 days ago
Daily – Vickers Top Insider Picks for 05/02/2025
Business Wire
8 days ago
RenovoRx to Host First Quarter 2025 Financial Results Conference Call on May 15th at 4:30 p.m. ET
Compare RNXT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "RNXT RenovoRx Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.